GE Healthcare Life Sciences Licenses Mammalian Cell-Line Knowhow from Promosome
GE Healthcare Life Sciences inked a licensing agreement that gave it exclusive rights to a suite of mammalian cell-line development technologies developed by Promosome for increasing protein expression in mammalian cell culture. Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.
“The biopharmaceutical industry is constantly looking for ways to improve efficiency and increase flexibility,” said Morgan Norris, general manager for upstream products, bioprocess, GE Healthcare Life Sciences. “Promosome’s technologies provide a powerful way to drive up protein yields and, more excitingly, boost the output of cell lines for hard-to-express proteins to a level where large-scale manufacturing becomes viable and previously disregarded therapies can be progressed.”